Results 31 to 40 of about 49,931 (273)

Debate: Are surrogate end-point studies worth the effort?

Current Controlled Trials in Cardiovascular Medicine, 2000
Surrogate end-points of cardiovascular disease can provide useful information in cross-sectional, prospective and interventional studies. They provide information on association with risk factors, natural history and factors associated with disease ...
Elkeles Robert S, Valabhji Jonathan
doaj   +1 more source

Surrogate endpoint biomarkers for cervical cancer chemoprevention trials [PDF]

, 1995
Cervical intraepithelia neoplasia (CIN) represents a spectrum of epithelial changes that provide an excellent model for developing chemopreventive interventions for cervical cancer.
Brenner, Dean E., Ruffin, Mack T., Johnston, Carolyn M., Lancaster, Wayne D., Ogaily, Mohammed S., Gregoire, Lucie   +5 more
core   +1 more source

Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation schema (BSES)

BMC Medical Research Methodology, 2012
Background Blood pressure is considered to be a leading example of a valid surrogate endpoint. The aims of this study were to (i) formally evaluate systolic and diastolic blood pressure reduction as a surrogate endpoint for stroke prevention and (ii ...
Lassere Marissa N, Johnson Kent R, Schiff Michal, Rees David   +3 more
doaj   +1 more source

An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.

PLoS ONE, 2013
It is widely acknowledged that new regimens are urgently needed for the treatment of tuberculosis. The primary endpoint in the Phase III trials is a composite outcome of failure at the end of treatment or relapse after stopping treatment. Such trials are
Patrick P J Phillips, Katherine Fielding, Andrew J Nunn   +2 more
doaj   +1 more source

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia

Journal of Hematology & Oncology, 2021
Quantification of measurable residual disease (MRD) provides critical prognostic information in acute myeloid leukemia (AML). A variety of platforms exist for MRD detection, varying in their sensitivity and applicability to individual patients.
Marisa J. L. Aitken, Farhad Ravandi, Keyur P. Patel, Nicholas J. Short   +3 more
doaj   +1 more source

Hierarchy of evidence for surrogate endpoint validity.

, 2019
Hierarchy of evidence for surrogate endpoint validity.
Petra Brhlikova (833194), Catherine Schuster Bruce (7365518), Joseph Heath (811695), Patricia McGettigan (203640)   +3 more
core   +1 more source

Figure 6: Potential Reasons for Surrogate Endpoint Failure

, 2019
(A) The surrogate endpoint is not in the causal pathway of the disease state. (B) There are several causal pathways of the disease state, but the intervention only impacts the pathway mediated by the surrogate endpoint.
Jennifer A. Rymer (6821558), L. Kristin Newby (772491)   +1 more
core   +1 more source

Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers [PDF]

, 2003
At the Second International Conference on Cervical Cancer, held April 11-14, 2002, experts in cervical cancer prevention, detection, and treatment reviewed the need for more research in chemoprevention, including prophylactic and therapeutic vaccines ...
Cornelison, Terri L, Alvarez, Ronald D, Follen, Michele, Walker, Joan L, Richards‐Kortum, Rebecca, Bell, Maria C, Roy, Krishnendu, Sastry, Jagannadha, Meyskens, Frank L, Storthz, Karen Adler   +9 more
core   +1 more source

Comparing Biomarkers as Principal Surrogate Endpoints [PDF]

Biometrics, 2011
Recently a new definition of surrogate endpoint, the "principal surrogate," was proposed based on causal associations between treatment effects on the biomarker and on the clinical endpoint. Despite its appealing interpretation, limited research has been conducted to evaluate principal surrogates, and existing methods focus on risk models that consider
Huang, Ying, Gilbert, Peter B.
openaire   +3 more sources

Organ‐specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides

FEBS Letters, EarlyView.
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley   +1 more source